Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Phase 3 Study to Confirm the Safety and Efficacy of T89 in Patients With Stable Angina Pectoris, With an Extended Open-label Period to Evaluate the Long-term Safety

NCT03789552 is registered in ClinicalTrials.gov with Tasly Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03789552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03789552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Phase 3 Study to Confirm the Safety and Efficacy of T89 in Patients With Stable Angina Pectoris, With an Extended Open-label Period to Evaluate the Long-term Safety
Lead sponsor
Tasly Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
August 1, 2019
Completion date
March 31, 2027
Enrollment
765 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic stable angina pectoris